Sugi Predict

Sugi Predict / Compounds / SCHEMBL446699

SCHEMBL446699

SCHEMBL446699

Cc1ncc(CN2CCC(CO)(Cc3cccc(Cl)c3)CC2)n1Cc1ccc(C#N)cc1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 4/20 0.53
▸ FNTB P49356 4/20 0.53
▸ PGGT1B P53609 4/20 0.53
▸ MEN1 O00255 7/20 0.47
▸ KMT2A Q03164 7/20 0.47
▸ RECQL P46063 1/20 0.47
▸ MAPT P10636 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ GAA P10253 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.44
▸ OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7838097 0.94 FNTA (0.55) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL7839865 0.92 FNTA (0.53) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL7856913 0.90 FNTA (0.61) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL7839572 0.90 FNTA (0.55) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL7839160 0.88 NPSR1 (0.53) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL7839131 0.88 FNTA (0.51) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL7847643 0.87 FNTA (0.48) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL29372490 0.87 FNTA (0.48) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL444276 0.87 FNTA (0.48) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL7848346 0.87 FNTA (0.49) FNTAFNTBPGGT1BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140301976-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. 2014-10-09 — — US claimed
US-8779171-B2 Hydroxamates as therapeutic agents PHARMACYCLICS, INC. (US) 2014-07-15 — — US claimed
US-20130142758-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2013-06-06 — — US claimed
EP-0944388-A4 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 2001-08-16 — — EP claimed
EP-0944388-A2 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-09-29 — — EP claimed
WO-1997038665-A2 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-23 — — WO claimed
US-20260000691-A1 COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT JENNINGS BARBARA BROOKE (US) 2026-01-01 — — US disclosed
EP-4552697-A2 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2025-05-14 — — EP disclosed
EP-3514151-B1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2025-04-23 — — EP disclosed
US-20240308979-A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2024-09-19 — — US disclosed
US-11505541-B2 Protein kinase C inhibitors and methods of their use NOVARTIS AG (CH) 2022-11-22 — — US disclosed
CN-108289922-B Therapeutic methods and compositions for treating non-small cell lung cancer 友杏生技医药股份有限公司 2022-02-08 — — CN disclosed
US-20210387962-A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2021-12-16 — — US disclosed
US-6248756-B1 Inhibitors of farnesyl-protein transferase MERCK & CO., INC. 2001-06-19 — — US disclosed
US-6245759-B1 PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS MERCK & CO., INC. 2001-06-12 — — US disclosed
WO-2001028993-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2001-04-26 — — WO disclosed
WO-2001017995-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-03-15 — — WO disclosed
WO-2000053605-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2000-09-14 — — WO disclosed
EP-0944388-A2 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-09-29 — — EP disclosed
WO-1997038665-A2 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308979-A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE PRKCA, PRKCB, PRKCH FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885
US-20210387962-A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE PRKCA, PRKCB, PRKCH FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885
US-20130142758-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS HDAC1, HDAC3, HDAC5 FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885
US-20260000691-A1 COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT PDK1, IP6K1, IP6K3 FNTA 3572/4885FNTB 2992/4885PGGT1B 3876/4885
US-11505541-B2 Protein kinase C inhibitors and methods of their use PRKCA, PRKCB, PRKCH FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885
US-20140301976-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS HDAC1, HDAC3, HDAC5 FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.